Recent Updates
Recently added Catalysts
PHAR Positive Sentiment

Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Key Takeaway: Pharming Group N.V. will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Fabrice Chouraqui and CMO Anurag Relan will present on February 25. A live webcast of the presentation will be available on Pharming's website, and investors can schedule one-on-one meetings with management.
Price reaction · baseline $15.42 (2026-02-13 close) · hit pre-market · clean, no other PHAR news in the window
day 0 close
+5.7%
day 1 · peak
+8.8%
day 3
+6.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Pharming is actively participating in a prominent healthcare conference.
  • The presentation will be led by key executives, showcasing leadership.
  • Opportunity for one-on-one meetings indicates investor engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
9.3%
average across 4 past catalysts
Lead asset
Recombinant human C1 inhibitor
Phase 3 · Hereditary Angioedema

Full Press Release Details

Leiden, theNetherlands, February 17, 2026:Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer 36thAnnual Healthcare Life Sciences Conference being held virtually on February 25-26, 2026.
Fabrice Chouraqui, Chief Executive Officer, and Anurag Relan, M.D., Chief Medical Officer, will present on Wednesday, February 25 at 12:40pm ET/18:40 CET. A live webcast and replay of the presentation will be made available in the “Upcoming Events” and “News” sections of Pharming’s website.
To schedule a one-on-one meeting with Pharming’s management team, please contact Investor Relations atinvestor@pharming.comor your Oppenheimer representative.
About Pharming Group N.V.Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.
For more information, visitwww.pharming.comand find us onLinkedIn.
For further public information, contact:Investor RelationsMichael Levitan, VP Investor Relations & Corporate CommunicationsT: +1 (908) 705 1696E:investor@pharming.com
Media RelationsGlobal: Saskia Mehring, Corporate Communications ManagerT: +31 6 28 32 60 41E:media.relations@pharming.comU.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)T: +1 (917) 882-9038Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)T: +31 6 53 81 64 27

Frequently Asked Questions

When is Pharming's presentation at the conference?

Pharming's presentation is scheduled for February 25, 2026, at 12:40pm ET.

Who will present for Pharming at the conference?

CEO Fabrice Chouraqui and CMO Anurag Relan will present.

How can investors schedule meetings with Pharming's management?

Investors can contact Investor Relations to schedule one-on-one meetings.

Where can I watch the Pharming presentation?

The presentation will be available via live webcast on Pharming's website.

Last updated: Feb 17, 2026